145 related articles for article (PubMed ID: 38093906)
1. Treatment Patterns of Long-Acting Somatostatin Analogs for Neuroendocrine Tumors.
Clarke CN; Cockrum P; Beveridge TJR; Jerry M; McMorrow D; Tran AT; Phan AT
J Health Econ Outcomes Res; 2023; 10(2):121-131. PubMed ID: 38093906
[No Abstract] [Full Text] [Related]
2. Patterns of Care Among Real-World Patients with Metastatic Neuroendocrine Tumors.
Klink AJ; Feinberg B; Yu HT; Ray D; Pulgar S; Phan A; Vinik A
Oncologist; 2019 Oct; 24(10):1331-1339. PubMed ID: 31015313
[TBL] [Abstract][Full Text] [Related]
3. Antiproliferative Effect of Above-Label Doses of Somatostatin Analogs for the Management of Gastroenteropancreatic Neuroendocrine Tumors.
Diamantopoulos LN; Laskaratos FM; Kalligeros M; Shah R; Navalkissoor S; Gnanasegaran G; Banks J; Smith J; Jacobs B; Galanopoulos M; Mandair D; Caplin M; Toumpanakis C
Neuroendocrinology; 2021; 111(7):650-659. PubMed ID: 32541155
[TBL] [Abstract][Full Text] [Related]
4. Treatment adherence and persistence with long-acting somatostatin analog therapy for the treatment of acromegaly: a retrospective analysis.
Gurel MH; Han Y; Stevens AL; Furtado A; Cox D
BMC Pharmacol Toxicol; 2017 Apr; 18(1):22. PubMed ID: 28372573
[TBL] [Abstract][Full Text] [Related]
5. A qualitative study to understand the experience of somatostatin analog treatments from the perspective of patients with neuroendocrine tumors.
Seo C; Horodniceanu E; Shah R; Goldstein G; Ray D; Bennett B; Phan A; McCarrier K
Support Care Cancer; 2022 Jul; 30(7):6307-6316. PubMed ID: 35476113
[TBL] [Abstract][Full Text] [Related]
6. Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors.
Saif MW; Parikh R; Ray D; Kaye JA; Kurosky SK; Thomas K; Ramirez RA; Halfdanarson TR; Beveridge TJR; Mirakhur B; Nagar SP; Soares HP
J Gastrointest Oncol; 2019 Aug; 10(4):674-687. PubMed ID: 31392048
[TBL] [Abstract][Full Text] [Related]
7. Prescribing Characteristics of Octreotide Immediate-Release and Long-Acting Release in Patients with Neuroendocrine Tumors.
Cheng Y; Anthony L; Delcher C; Moga DC; Chauhan A; Huang B; Adams V
Oncologist; 2023 Jun; 28(6):479-485. PubMed ID: 36994847
[TBL] [Abstract][Full Text] [Related]
8. LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.
Fisher GA; Wolin EM; Liyanage N; Lowenthal SP; Mirakhur B; Pommier RF; Shaheen M; Vinik AI;
Endocr Pract; 2018 Mar; 24(3):243-255. PubMed ID: 29547049
[TBL] [Abstract][Full Text] [Related]
9. Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET).
Ström T; Kozlovacki G; Myrenfors P; Almquist M
Patient Prefer Adherence; 2019; 13():1799-1807. PubMed ID: 31695341
[TBL] [Abstract][Full Text] [Related]
10. Analysis of Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs Between Octreotide and Lanreotide Among Patients With Neuroendocrine Tumors.
Huynh L; Cai B; Cheng M; Lax A; Lejeune D; Duh MS; Kim MK
Pancreas; 2019 Oct; 48(9):1126-1135. PubMed ID: 31593022
[TBL] [Abstract][Full Text] [Related]
11. Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors.
Allaw MB; Switchenko JM; Khalil L; Wu C; Alese OB; Akce M; Draper A; Jones AT; El-Rayes B; Shaib W
Oncology; 2022; 100(3):131-139. PubMed ID: 35078191
[TBL] [Abstract][Full Text] [Related]
12. EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.
Vinik AI; Wolin EM; Liyanage N; Gomez-Panzani E; Fisher GA;
Endocr Pract; 2016 Sep; 22(9):1068-80. PubMed ID: 27214300
[TBL] [Abstract][Full Text] [Related]
13. PRESTO 2: An International Survey to Evaluate Patients' Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly.
O'Toole D; Kunz PL; Webb SM; Goldstein G; Khawaja S; McDonnell M; Boiziau S; Gueguen D; Houchard A; Ribeiro-Oliveira A; Prebtani A
Adv Ther; 2023 Feb; 40(2):671-690. PubMed ID: 36502449
[TBL] [Abstract][Full Text] [Related]
14. Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting.
Harrow B; Fagnani F; Nevoret C; Truong-Thanh XM; de Zélicourt M; de Mestier L
Adv Ther; 2022 Apr; 39(4):1754-1771. PubMed ID: 35190997
[TBL] [Abstract][Full Text] [Related]
15. Comparing the Cost of Treatment with Octreotide Long-Acting Release versus Lanreotide in Patients with Metastatic Gastrointestinal Neuroendocrine Tumors.
Ayyagari R; Neary M; Li S; Rokito A; Yang H; Xie J; Benson AB
Am Health Drug Benefits; 2017 Nov; 10(8):408-415. PubMed ID: 29263774
[TBL] [Abstract][Full Text] [Related]
16. Patients' satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors.
Darden C; Price M; Ray D; Goldstein G; Goss D; Bennett L; Garbinsky D; Thota R
J Patient Rep Outcomes; 2021 Sep; 5(1):82. PubMed ID: 34491454
[TBL] [Abstract][Full Text] [Related]
17. Real-world treatment patterns of gastrointestinal neuroendocrine tumors: A claims database analysis.
Benson AB; Broder MS; Cai B; Chang E; Neary MP; Papoyan E
World J Gastroenterol; 2017 Sep; 23(33):6128-6136. PubMed ID: 28970728
[TBL] [Abstract][Full Text] [Related]
18. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
Ricci S; Antonuzzo A; Galli L; Ferdeghini M; Bodei L; Orlandini C; Conte PF
Ann Oncol; 2000 Sep; 11(9):1127-30. PubMed ID: 11061606
[TBL] [Abstract][Full Text] [Related]
19. Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors.
Saif MW; Fu J; Smith MH; Weinstein B; Relias V; Daly KP
J Pancreat Cancer; 2018; 4(1):64-71. PubMed ID: 30788459
[No Abstract] [Full Text] [Related]
20. A Real-World Observational Study of the Use and Associated Costs of Treating Neuroendocrine Tumors With Somatostatin Analogs in Canada.
Cheung WY; LaForty C; Liovas A; McKechnie H; Loree JM
Pancreas; 2022 Oct; 51(9):1146-1152. PubMed ID: 37078938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
